Proprio, a Seattle, WA-based surgical technology company, secured $43 million in Series B funding from new and existing investors.
The capital fuels commercialization to address significant demand for Proprio's AI-driven surgical navigation platform in the U.S and overseas.
The flagship product of Proprio, called Paradigm, achieved a major milestone this year by obtaining 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Paradigm is a surgical navigation platform that utilizes the power of light field technology and artificial intelligence to create a real-time 3D visualization of surgeries. With its unique Volumetric Intelligence feature, Paradigm combines medical images with live data from its sensor suite, providing surgeons with valuable and actionable information during procedures.
Proprio's live, 3D, multi-modal data represents a significant upgrade over current static approaches to surgical navigation and the company plans to apply its technology to many surgical specialties beyond its first targets in spine procedures.
"We are just beginning to reveal the potential applications of Proprio's technology and data," said Gabriel Jones, CEO and co-founder of Proprio. "This investment arrives at a pivotal moment, as we perform our first-in-human cases and bring Paradigm to patients around the world. Together, these milestones are a testament to the unparalleled capabilities of the Proprio Paradigm and its potential to revolutionize surgery."
Company: Proprio, Inc.
Raised: $43.0M
Round: Series B
Funding Month: July 2023
Lead Investors: Undisclosed
Additional Investors: Undisclosed
Company Website: https://www.propriovision.com/
Software Category: Surgical Navigation Platform
About the Company: Proprio is a leading surgical technology company creating The New Way of Seeing in surgery. Using advancements in light field computer vision and AI, the Proprio Paradigm system synthesizes data from multiple inputs for navigating anatomy and surgical environments in 3D. Proprio's mission is to dramatically improve clinical and economic outcomes by leveraging advanced AI and data collection capabilities with the potential to provide predictive intelligence in surgery.
Source: https://www.propriovision.com/news/proprio-raises-43m-series-b-funding-to-fuel-commercialization